Novartis Puts Combination, Cellular Therapies In Spotlight As It Revamps R&D Portfolio
Novartis says it has entered a transformational period of growth as its oncologic products continue to advance and its focus expands to include dedicated R&D units for dermatology, heart failure, respiratory and cell therapy.
You may also be interested in...
CEO Joe Jimenez delivers on his strategy to free up resources at Novartis by divesting its non-core blood transfusion diagnostics business for $1.7 billion.
As FDA looks toward more flexible cancer drug development standards, advisory panel indicates Novartis’ proposed pediatric indications for CDK inhibitor could be candidate for single-arm studies.
The independent, family-controlled German group has signed a third R&D pact with Danish biotech Gubra to develop poly-agonist peptides for obesity.